Nike (NKE 2.87%) CEO Elliott Hill took the reins of the vaunted sportswear giant a year-and-a-half ago with a tall task ahead of him. Hill was asked to turn around the struggling Swoosh, which was facing the biggest drawdown in its history as a publicly traded company. Revenue growth had fallen as low as negative double digits, as Nike was losing share to upstart challengers like Deckers' Hoka and...
Nike (NKE 2.87%) CEO Elliott Hill took the reins of the vaunted sportswear giant a year-and-a-half ago with a tall task ahead of him. Hill was asked to turn around the struggling Swoosh, which was facing the biggest drawdown in its history as a publicly traded company. Revenue growth had fallen as low as negative double digits, as Nike was losing share to upstart challengers like Deckers' Hoka and On Holding. Since taking over Nike, Hill has made a lot of changes. He's refreshed the management team, streamlined the organizational structure, and brought the focus of the company back to sport. He's also stepped up investments in innovation, pulled back on legacy styles, and reestablished relationships with key wholesale partners after the company overinvested in the direct-to-consumer channel. Some of those efforts have paid off. Nike's revenue has stabilized with sales up 1% to $12.4 billion in the fiscal second quarter, its most recent one, and it's returned to growth in running, one of its biggest categories. However, Nike has slumped in recent months and is back to hovering around an 8-year low as margins have continued to compress as the company invests in the turnaround. With the share price now below $55, Wall Street has taken notice. Wall Street smells opportunity Barclays upgraded the stock on Wednesday, lifting its rating from neutral to a buy-equivalent and raising its price target from $64 to $73. Barclays noted Nike's improving inventory levels, which should help lift margins, and that the recovery in running could pave the way for the rest of the business. Wells Fargo also recently reiterated its buy-equivalent rating on the stock, though it removed Nike from its list of top picks. Finally, Jefferies said that commentary from Dick's Sporting Goods in its fourth-quarter report gives it confidence in Nike's wholesale recovery. Expand NYSE : NKE Nike Today's Change ( -2.87 %) $ -1.60 Current Price $ 54.10 Key Data Points Market Cap $82B Day's Range $ 54.03 ...
Key Points CEO Elliott Hill has made some improvements in his year-and-a-half running Nike. However, revenue is still flat, and profits are falling. The stock isn't cheap, but if the company can get back to profit growth, the stock should rebound. 10 stocks we like better than Nike › Nike (NYSE: NKE) CEO Elliott Hill took the reins of the vaunted sportswear giant a year-and-a-half ago with a tall ...
Key Points CEO Elliott Hill has made some improvements in his year-and-a-half running Nike. However, revenue is still flat, and profits are falling. The stock isn't cheap, but if the company can get back to profit growth, the stock should rebound. 10 stocks we like better than Nike › Nike (NYSE: NKE) CEO Elliott Hill took the reins of the vaunted sportswear giant a year-and-a-half ago with a tall task ahead of him. Hill was asked to turn around the struggling Swoosh, which was facing the biggest drawdown in its history as a publicly traded company. Revenue growth had fallen as low as negative double digits, as Nike was losing share to upstart challengers like Deckers' Hoka and On Holding. Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue » Since taking over Nike, Hill has made a lot of changes. He's refreshed the management team, streamlined the organizational structure, and brought the focus of the company back to sport. He's also stepped up investments in innovation, pulled back on legacy styles, and reestablished relationships with key wholesale partners after the company overinvested in the direct-to-consumer channel. Some of those efforts have paid off. Nike's revenue has stabilized with sales up 1% to $12.4 billion in the fiscal second quarter, its most recent one, and it's returned to growth in running, one of its biggest categories. However, Nike has slumped in recent months and is back to hovering around an 8-year low as margins have continued to compress as the company invests in the turnaround. With the share price now below $55, Wall Street has taken notice. Wall Street smells opportunity Barclays upgraded the stock on Wednesday, lifting its rating from neutral to a buy-equivalent and raising its price target from $64 to $73. Barclays noted Nike's improving inventory levels, which should h...
Key Points Medicare eligibility generally begins at 65. If you're still working, you may want to hold off on enrolling if you have good health coverage. That's not the only reason to wait on Medicare. The $23,760 Social Security bonus most retirees completely overlook › Age 65 is an important milestone in the context of healthcare. That's when most people become eligible to enroll in Medicare. You...
Key Points Medicare eligibility generally begins at 65. If you're still working, you may want to hold off on enrolling if you have good health coverage. That's not the only reason to wait on Medicare. The $23,760 Social Security bonus most retirees completely overlook › Age 65 is an important milestone in the context of healthcare. That's when most people become eligible to enroll in Medicare. Your initial Medicare enrollment window actually begins three months before the month of your 65th birthday, allowing you to sign up ahead of time and put that coverage in place right away. But if you're still working at age 65, you may want to hold off on enrolling in Medicare. And the reason may surprise you. Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue » The less obvious reason to wait on Medicare If you're still working when you become eligible for Medicare, it may not make sense to sign up if you have good health coverage through your employer. While Medicare Part A, which covers hospital care, is free for most enrollees, Part B, which covers outpatient care, comes with a monthly premium. And why pay that premium if you have a workplace plan you're happy with? But there's a less obvious reason to hold off on Medicare enrollment. Waiting to sign up could allow you to keep contributing to a health savings account, or HSA. HSAs are available to people enrolled in high-deductible health insurance plans. And what's great about them is that they're triple tax-advantaged. With an HSA: Contributions are made with pre-tax dollars Invested funds get to grow tax-free Withdrawals are tax-free as long as they're used for qualifying healthcare expenses Once you enroll in Medicare, though, HSA contributions are banned. This holds true even if you only sign up for Part A, which some people do in conjunction with havin...
Cryo-Cell International ( CCEL ) on Thursday said it received a notice from NYSE American stating the company is not in compliance with certain continued listing standards. The exchange cited the company’s stockholders’ deficit as of November 30, 2025, and net losses in two of its three most recent fiscal years ended November 30, 2023, 2024 and 2025. Cryo-Cell said the notice has no immediate effe...
Cryo-Cell International ( CCEL ) on Thursday said it received a notice from NYSE American stating the company is not in compliance with certain continued listing standards. The exchange cited the company’s stockholders’ deficit as of November 30, 2025, and net losses in two of its three most recent fiscal years ended November 30, 2023, 2024 and 2025. Cryo-Cell said the notice has no immediate effect on the listing or trading of its common stock and that it plans to submit a compliance plan to the exchange. If accepted, the company could receive up to 18 months to regain compliance. Source: Press Release More on CRYO-CELL International Seeking Alpha’s Quant Rating on CRYO-CELL International Historical earnings data for CRYO-CELL International Financial information for CRYO-CELL International
Strategic initiatives and new customers are delivering improved underlying performance, masked by ongoing sector and macroeconomic environment business pressures Launched significant share of wallet expansions with two major customers and onboarded a new full-service restaurant customer Reduced debt by $2.0 million in the quarter, bringing full year debt reduction to $13.2 million, or 16.4% IRVING...
Strategic initiatives and new customers are delivering improved underlying performance, masked by ongoing sector and macroeconomic environment business pressures Launched significant share of wallet expansions with two major customers and onboarded a new full-service restaurant customer Reduced debt by $2.0 million in the quarter, bringing full year debt reduction to $13.2 million, or 16.4% IRVING, Texas, March 12, 2026 (GLOBE NEWSWIRE) -- Quest Resource Holding Corporation (Nasdaq: QRHC) (“Quest” or the “Company”), a national leader in environmental waste and recycling services, today announced financial results for the fourth quarter and fiscal year ended December 31, 2025. Fourth Quarter 2025 Highlights Revenue was $58.9 million, a 15.8% decrease compared with the fourth quarter of 2024, and a 7.0% decrease from the third quarter of 2025. Gross profit was $9.1 million, a 15.1% decrease compared with the fourth quarter of 2024, and a 20.6% decrease from the third quarter of 2025. Gross margin was 15.5% of revenue, compared with 15.3% for the fourth quarter of 2024. GAAP net loss was $1.7 million, compared with a net loss of $9.5 million for the fourth quarter of 2024. GAAP net loss per basic and diluted share attributable to common stockholders was $(0.08), compared with $(0.46) for the fourth quarter of 2024. Adjusted EBITDA was $2.1 million, compared with $1.7 million for the fourth quarter of 2024. Fiscal Year 2025 Highlights Revenue was $250.2 million, a 13.3% decrease compared with the same period of 2024. Gross profit was $42.5 million, a 14.9% decrease compared with the same period of 2024. Gross margin was 17.0% of revenue, compared with 17.3% for the same period of 2024. GAAP net loss was $15.4 million, compared with a net loss of $15.1 million for the same period of 2024. GAAP net loss per basic and diluted share attributable to common stockholders was $(0.73), which is consistent with the same period of 2024. Adjusted EBITDA was $9.3 million compared to...
The Global X NASDAQ 100 Covered Call ETF ( QYLD ) boasts an almost 12% yield. But does this make it a good income-generating investment long-term? In this analysis, I want to explain why QYLD’s distributions and total returns behaved a certain way. This ETF's portfolio construction is transparent. But it does not mean that it works on the Nasdaq-100. Historically, QYLD has not produced a favorable...
The Global X NASDAQ 100 Covered Call ETF ( QYLD ) boasts an almost 12% yield. But does this make it a good income-generating investment long-term? In this analysis, I want to explain why QYLD’s distributions and total returns behaved a certain way. This ETF's portfolio construction is transparent. But it does not mean that it works on the Nasdaq-100. Historically, QYLD has not produced a favorable result for income-seeking investors. Other similar covered call ETFs do a better job by mitigating QYLD’s structural issues. QYLD Portfolio Construction in a Nutshell QYLD has been around since 2013. It is one of the oldest covered call ETFs that is appealing to income investors. The concept behind it is relatively simple to understand. The fund buys the Nasdaq-100 and then sells at-the-money call options on it on a monthly basis. At-the-money options generate income that QYLD distributes to investors on a monthly basis. The fund has a rule that it does not distribute all of the premium income received. Instead, QYLD distributes 50% of the premiums received or 1% of the fund’s net asset value, whichever is lower. The remaining balance gets reinvested back into the fund. Why QYLD’s Covered Call Strategy Does Not Work on Nasdaq-100 Here is why QYLD’s investment process does not work on the Nasdaq-100, in my opinion. The Nasdaq-100 is very volatile and growth-oriented. It can make strong moves to both the upside and the downside. The most important job of a covered call ETF is to capture as much of that upside while keeping its downside low. To capture this upside, covered call funds have two main levers to pull. First is portfolio coverage by sold call options. If a fund sells call options on, say, 50% of its stock portfolio, it can capture future upside on the remaining 50%. Many covered call ETFs like QQQI, JEPQ, and GPIQ do not sell call options on their entire portfolios. Conversely, QYLD writes call options on 100% of its portfolio. The upshot is that it captures a lot ...
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Astera Labs is expanding into European markets through targeted acquisitions. The company is using these deals to build a broader footprint beyond its existing regions. This move marks a shift in its global growth approach that had not been highlighted in earl...
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Astera Labs is expanding into European markets through targeted acquisitions. The company is using these deals to build a broader footprint beyond its existing regions. This move marks a shift in its global growth approach that had not been highlighted in earlier updates. For investors tracking NasdaqGS:ALAB, this acquisition-led expansion adds a new piece to the story beyond prior discussion of partnerships, margins, and product mix. The shares trade at $124.71, with a 7 day return of 9.6% and a 1 year return of 81.2%, while the year to date return sits at a 30.5% decline and the 30 day return at a 33.5% decline. Europe-focused acquisitions could change how you think about where future revenue might come from and how the business is positioned globally. As the company integrates these deals, the key questions will be execution, the quality of acquired assets, and how well they align with Astera Labs’ existing product and customer base. Stay updated on the most important news stories for Astera Labs by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Astera Labs. NasdaqGS:ALAB 1-Year Stock Price Chart See which insiders are buying and buying and selling Astera Labs following this latest news. Quick Assessment ✅ Price vs Analyst Target : At $124.71, the share price sits about 40% below the consensus analyst target of $206.75. ❌ Simply Wall St Valuation : Shares are trading around 37% above Simply Wall St's estimated fair value, which flags a rich valuation. ❌ Recent Momentum: The 30 day return of about 33.5% decline shows weak recent momentum despite the acquisition news. There is only one way to know the right time to buy, sell or hold Astera Labs. Head to Simply Wall St's company report for the latest analysis of Astera Labs's Fair Value. Key Considerations 📊 Europe ...
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Astera Labs is expanding into European markets through targeted acquisitions. The company is using these deals to build a broader footprint beyond its existing regions. This move marks a shift in its global growth approach that had not been highlighted in earl...
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Astera Labs is expanding into European markets through targeted acquisitions. The company is using these deals to build a broader footprint beyond its existing regions. This move marks a shift in its global growth approach that had not been highlighted in earlier updates. For investors tracking NasdaqGS:ALAB, this acquisition-led expansion adds a new piece to the story beyond prior discussion of partnerships, margins, and product mix. The shares trade at $124.71, with a 7 day return of 9.6% and a 1 year return of 81.2%, while the year to date return sits at a 30.5% decline and the 30 day return at a 33.5% decline. Europe-focused acquisitions could change how you think about where future revenue might come from and how the business is positioned globally. As the company integrates these deals, the key questions will be execution, the quality of acquired assets, and how well they align with Astera Labs’ existing product and customer base. Stay updated on the most important news stories for Astera Labs by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Astera Labs. NasdaqGS:ALAB 1-Year Stock Price Chart See which insiders are buying and buying and selling Astera Labs following this latest news. Quick Assessment ✅ Price vs Analyst Target : At $124.71, the share price sits about 40% below the consensus analyst target of $206.75. ❌ Simply Wall St Valuation : Shares are trading around 37% above Simply Wall St's estimated fair value, which flags a rich valuation. ❌ Recent Momentum: The 30 day return of about 33.5% decline shows weak recent momentum despite the acquisition news. There is only one way to know the right time to buy, sell or hold Astera Labs. Head to Simply Wall St's company report for the latest analysis of Astera Labs's Fair Value. Key Considerations 📊 Europe ...
April Nymex natural gas (NGJ26) on Thursday closed up +0.024 (+0.75%). Nat-gas prices on Thursday rallied in sympathy with crude oil and European gas prices amid the Iran war, which is dragging on. Iran's Supreme Leader Ayatollah Mojtaba Khamenei said on Thursday that Iran's leverage of closing the Strait of Hormuz should be used, and attacks on Gulf Arab neighbors will continue. Also, UK Defense ...
April Nymex natural gas (NGJ26) on Thursday closed up +0.024 (+0.75%). Nat-gas prices on Thursday rallied in sympathy with crude oil and European gas prices amid the Iran war, which is dragging on. Iran's Supreme Leader Ayatollah Mojtaba Khamenei said on Thursday that Iran's leverage of closing the Strait of Hormuz should be used, and attacks on Gulf Arab neighbors will continue. Also, UK Defense Secretary Healey said it is increasingly evident that Iran is laying mines in the Strait of Hormuz, which would keep the waterway closed for the foreseeable future. Don’t Miss a Day: Nat-gas prices fell back from their best level after EIA nat-gas inventories fell -38 bcf for the week ended March 6, a smaller draw than expectations of -41 bcf. Mixed weather forecasts also weighed on nat-gas prices, as the Commodity Weather Group forecast well-above-average temperatures across the western half of the US from March 17-21, and cooler readings in the East. Nat-gas prices surged last week, with European nat-gas prices climbing to a 3-year high last Tuesday due to the war in Iran. Last Monday, Qatar shut its Ras Laffan plant, the world's largest natural gas export facility, after it was targeted by an Iranian drone attack. The Ras Laffan plant accounts for about 20% of global liquefied natural gas supply, and its closure could boost US nat-gas exports. US (lower-48) dry gas production on Thursday was 112.3 bcf/day (+5.3% y/y), according to BNEF. Lower-48 state gas demand on Thursday was 84.7 bcf/day (+7.8% y/y), according to BNEF. Estimated LNG net flows to US LNG export terminals on Thursday were 20.2 bcf/day (+5.4% w/w), according to BNEF. Projections for higher US nat-gas production are bearish for prices. On February 17, the EIA raised its forecast for 2026 US dry nat-gas production to 109.97 bcf/day from last month's estimate of 108.82 bcf/day. US nat-gas production is currently near a record high, with active US nat-gas rigs posting a 2.5-year high last Friday. As a positiv...